tivantinib (ARQ 197) / Merck (MSD), Kyowa Kirin, Daiichi Sankyo  >>  Phase 2
Welcome,         Profile    Billing    Logout  

3 Trials

   Remove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
tivantinib (ARQ 197) / Daiichi Sankyo, Kyowa Kirin, Merck (MSD)
2009-015400-26: MULTICENTER PHASE 2 TRIAL OF ARQ 197 FOR SUBJECTS WITH RELAPSED OR REFRACTORY GERM CELL TUMORS

Ongoing
2
41
Europe, RoW
ARQ197, Capsule*
Daiichi Sankyo Pharma Development
Germ cell tumors (GCT) including testicular and non-central nervous system (non-CNS) extragonadal types.
 
 
NCT01542996: ARQ197 in Metastatic Triple-Negative Breast Cancer

Active, not recruiting
2
40
US
ARQ 197
Dana-Farber Cancer Institute
Breast Cancer
08/13
 
2014-002497-37: TIvantinib as Maintenance treatment in Extended Small-cell lung cancer Tivantinib come terapia di mantenimento nel carcinoma polmonare a piccole cellule avanzato

Ongoing
2
66
Europe
Tivantinib, ARQ197, Tablet
Istituto Oncologico del Veneto IRCCS – UOC Oncologia Medica 2, AIRC- Italian Cancer Research Association
Small Cell Lung Cancer (SCLC) after first-line platinum plus etoposide therapy Carcinoma polmonare a piccole cellule (SCLC) dopo terapia in prima linea con platino e etoposide, Lung Cancer Carcinoma polmonare, Diseases [C] - Cancer [C04]
 
 

Download Options